DMAC - DiaMedica Corp Total Debt to Capital

The daily price chart for DiaMedica Therapeutics (DMAC) based on the total debt-to-equity ratio is 0.00. DiaMedica Therapeutics focuses on developing stroke rehabilitation methods, relying on long-term revenue driven by patent protection. The business maintains high authority in the field of kidney protection by creating safe molecules. The project is currently awaiting regulatory approval, as the lack of sales temporarily limits profit growth.

Total debt-to-equity measures the proportion of borrowed funds relative to shareholders' equity, determining the degree of financial leverage. This metric allows an investor to assess bankruptcy risk during negative market shocks. By analyzing the current total debt-to-equity ratio on GURU.Markets, one can track the stability of the balance sheet structure. For DiaMedica Therapeutics (DMAC), a low debt load is expected, as a virtual business model utilizing production outsourcing minimizes capital expenditures.